- Home
- GILD vs FI Comparison
GILD vs FI Comparison
Compare GILD & FI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GILD
- FI
- Stock Information
- Founded
- GILD 1987
- FI 1984
- Country
- GILD United States
- FI United States
- Employees
- GILD N/A
- FI N/A
- Industry
- GILD Biotechnology: Biological Products (No Diagnostic Substances)
- FI Business Services
- Sector
- GILD Health Care
- FI Consumer Discretionary
- Exchange
- GILD Nasdaq
- FI Nasdaq
- Market Cap
- GILD 131.5B
- FI 116.3B
- IPO Year
- GILD 1992
- FI 1986
- Fundamental
- Price
- GILD $104.54
- FI $208.66
- Analyst Decision
- GILD Buy
- FI Strong Buy
- Analyst Count
- GILD 27
- FI 24
- Target Price
- GILD $105.32
- FI $240.65
- AVG Volume (30 Days)
- GILD 10.4M
- FI 3.4M
- Earning Date
- GILD 04-24-2025
- FI 04-24-2025
- Dividend Yield
- GILD 3.02%
- FI N/A
- EPS Growth
- GILD N/A
- FI 8.03
- EPS
- GILD 0.38
- FI 5.38
- Revenue
- GILD $28,754,000,000.00
- FI $20,456,000,000.00
- Revenue This Year
- GILD $1.80
- FI $4.85
- Revenue Next Year
- GILD $3.83
- FI $8.87
- P/E Ratio
- GILD $275.11
- FI $38.78
- Revenue Growth
- GILD 6.04
- FI 7.14
- 52 Week Low
- GILD $62.07
- FI $145.98
- 52 Week High
- GILD $119.96
- FI $238.59
- Technical
- Relative Strength Index (RSI)
- GILD 43.51
- FI 45.45
- Support Level
- GILD $97.32
- FI $191.12
- Resistance Level
- GILD $107.18
- FI $215.15
- Average True Range (ATR)
- GILD 3.94
- FI 9.33
- MACD
- GILD -0.45
- FI 0.20
- Stochastic Oscillator
- GILD 41.42
- FI 54.53
About GILD Gilead Sciences Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
About FI Fiserv Inc.
Fiserv is a leading provider of core processing and complementary services, such as electronic funds transfer, payment processing, and loan processing, for US banks and credit unions, with a focus on small and midsize banks. Through the merger with First Data in 2019, Fiserv also provides payment processing services for merchants. About 10% of the company's revenue is generated internationally.